Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
Authors:
- Mohamed El KassasMKMohamed El Kassas
- Nermeen AbdeenNANermeen Abdeen
- Dalia OmranDODalia Omran
- Mohamed AlboraieMAMohamed Alboraie
- Mohamed SalaheldinMSMohamed Salaheldin
- Mohamed EltabbakhMEMohamed Eltabbakh
- Rasha FarghalyRFRasha Farghaly
- Mohammed EmadeldeenMEMohammed Emadeldeen
- Shimaa AfifySAShimaa Afify
- Ahmed GhalwashAGAhmed Ghalwash
- 21 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (1S) , e877-e882
Abstract
Background: Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy. Objective: We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients, to determine sustained virological response (SVR)12 rates and to analyze the factors associated with response. Methods: A retrospective, single-center study including HCV-related decompensated cirrhosis patients who received DAAs. Demographic, laboratory and clinical data were analyzed. The SVR12 rate was the primary outcome measure. Secondary outcomes included the predictors of response, changes in the baseline model for end-stage liver disease and child-turcotte-pugh (CTP) scores, and fibroindices (APRI and fibrosis-4 index) at 12 weeks after treatment. Results: In total, 145 eligible patients (141 with CTP class B and 4 with class C) were enrolled in this study. SVR12 was achieved by 88.06% (118/134) of efficacy population on different DAAs regimens, Treatment was discontinued in 11 patients because of severe side effects without any deaths. Younger age showed a significant positive association with SVR12. Conclusions: DAAs can be used for the treatment of HCV-related decompensated liver disease, with acceptable SVR12 rates and safety profiles.Keywords
This publication has 24 references indexed in Scilit:
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialThe Lancet Infectious Diseases, 2016
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Liver transplantation for viral hepatitis in 2015World Journal of Gastroenterology, 2016
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapiesAlimentary Pharmacology & Therapeutics, 2015
- New era for management of chronic hepatitis C virus using direct antiviral agents: A reviewJournal of Advanced Research, 2015
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisHepatology, 2015
- Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosisWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2015
- Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirinJournal of Viral Hepatitis, 2012